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We compared the clinical features of 8 U.S. case-
patients with laboratory-confirmed severe acute respiratory
syndrome (SARS) to 65 controls who tested negative for
SARS coronavirus (SARS-CoV) infection. Shortness of
breath, vomiting, diarrhea, progressive bilateral infiltrates on
chest radiograph, and need for supplemental oxygen were
significantly associated with confirmed SARS-CoV infection.
T
he clinical course and outcomes of cases of severe
acute respiratory syndrome (SARS) in Asia and
Canada have been well described (1–6). Most of these
studies defined cases based on clinical and epidemiologic
criteria with or without laboratory evidence of SARS-asso-
ciated coronavirus (SARS-CoV) infection. In the event of
a subsequent outbreak, distinguishing clinical features
associated with SARS-CoV infection may help inform
decisions regarding patient evaluation and infection con-
trol practices while laboratory results are pending. We
describe the clinical characteristics of patients in the
United States with laboratory-confirmed SARS and com-
pare them to persons who tested negative for SARS-CoV
but had similar illnesses 
The Study
We defined a case-patient as a U.S. resident who met
the clinical and epidemiologic criteria for suspected or
probable SARS and had laboratory evidence of SARS-
CoV infection (7). Laboratory evidence of SARS-CoV
infection was defined as 1) isolation of SARS-CoV, 2)
detection of SARS-CoV RNA by polymerase chain reac-
tion (PCR), or 3) detection of antibodies against SARS-
CoV by using enzyme-linked immunosorbant assay or
indirect fluorescent-antibody assay (8,9).
After obtaining verbal consent, health officials used a
standard questionnaire to interview by telephone patients
with suspected or probable SARS and their healthcare
providers. Data collected included clinical symptoms, past
medical history, relevant exposures, physical examination,
radiographic and laboratory findings, and clinical course
and outcome. 
Case-patients with laboratory-confirmed SARS were
compared to a convenience sample of persons who met the
clinical and epidemiologic criteria for suspected or proba-
ble SARS but subsequently tested negative for SARS-CoV
infection. Controls had negative findings on all testing per-
formed for SARS-CoV, including the absence of antibody
against the virus in convalescent-phase serum samples
obtained >21 days after onset of symptoms. Statistical
analysis was performed with SAS software version 8.2
(SAS Institute, Cary, NC). Univariate odds ratios, 95%
confidence intervals, and p values for association were cal-
culated by using exact likelihood methods.
We identified 8 case-patients with laboratory-con-
firmed SARS-CoV infection in the United States. Dates of
onset of symptoms were from February 22 to May 24,
2003. The median age of case-patients was 43 years (range
22–53 years); 4 were women. Two case-patients were
pregnant (8 weeks’and 19 weeks’gestation) at the onset of
their illness. No other major underlying medical conditions
were noted. 
Seven case-patients reported travel to an area with com-
munity transmission of SARS in the 10 days before illness
onset, including Hong Kong (n = 4), Toronto (n = 2), and
Singapore (n = 1). One case-patient returned to the United
States 13 days before illness onset after traveling to Hong
Kong with her spouse, who was also a laboratory-con-
firmed SARS patient. Three (38%) patients visited a
healthcare facility during their travel in the 10 days before
illness onset, and 4 patients stayed at a hotel associated
with a well-defined SARS cluster (7).
Over the course of their illness, findings suggestive of
a lower respiratory tract infection developed in all 8
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USApatients with laboratory-confirmed SARS; these findings
included dyspnea (n = 8), rales (n = 5), and hypoxia (n =
5) (Table 1). Symptoms indicative of an upper respiratory
tract infection, including rhinorrhea and sore throat, were
reported less often. The most common symptoms at illness
onset included fever (n = 8), chills (n = 6), and headache
(n = 5). Four (50%) patients reported at least 1 respiratory
symptom at illness onset. In the remaining 4 patients, res-
piratory symptoms began 3–7 days after illness onset. The
median duration of symptoms before a patient sought med-
ical evaluation was 6 days (range 3–14 days). When
patients were first evaluated, the median recorded temper-
ature was 38.6°C (range 37.0°C–40.0°C); the median
recorded oxygen saturation on room air was 95% (range
87%–100%). 
Gastrointestinal symptoms were also prominent. Six
patients reported diarrhea, and 5 reported vomiting during
the course of their illness. When present, diarrhea occurred
a median of 3 days after onset (range 2–3 days) and was
noted before (n = 4), or within 48 hours (n = 2) of receiv-
ing antimicrobial therapy. Vomiting began a median of 5
days after onset (range 3–9 days). 
All 8 case-patients had radiographic evidence of pul-
monary infiltrates during the course of their illness
(Table 2). Bilateral pulmonary infiltrates developed in 7
patients during the course of illness with both interstitial
and alveolar involvement. Of these, 6 demonstrated wors-
ening chest radiographic findings in week 2 of illness.
The first abnormal chest radiograph was obtained a
median of 7 days after onset of symptoms (range 1–14
days). Six patients had an abnormal chest radiograph when
first evaluated, including 3 with bilateral infiltrates. Two
patients had unremarkable initial chest radiographs on
days 6 and 8 after onset, respectively, but were subsequent-
ly noted to have infiltrates on chest imaging obtained on
days 8 and 11 of their illness.
During the course of their illness, all 8 case-patients
received antibacterial therapy. Three patients also received
oseltamivir; none was treated with ribavirin. One patient
received corticosteroids. Seven patients were hospitalized
for a median of 8 days (range 6–15 days). Two patients
were admitted to the intensive care unit for 7 and 9 days,
respectively; no deaths occurred (Table 2).
Antibodies against SARS-CoV developed in all 8
patients; 3 had positive PCR findings in clinical specimens
(1 sputum and 2 stool specimens) (7). Variable levels of
clinical laboratory testing were performed (Table 2).
The 8 patients with laboratory-confirmed SARS were
compared to 65 SARS-CoV–negative controls (>18 years
old), of whom 14 (22%) had radiographic evidence of
pneumonia. Forty-four (68%) controls tested negative for
antibodies to SARS-CoVon serum obtained >28 days after
symptom onset; the remaining 21 (32%) controls had a
negative serologic finding for SARS-CoV 22–28 days
after illness onset.
Patients were similar to controls with regard to age and
sex. Fifty-eight (89%) controls reported travel to an area
with community transmission of SARS in the 10 days
before illness onset. However, patients were significantly
more likely than controls to have visited a healthcare facil-
ity during their travel (3/8 vs. 4/65; p = 0.03) or to have
stayed at the hotel associated with the SARS cluster (3/8
versus 1/65; p < 0.01).
Univariate analysis of clinical features showed that
dyspnea, hypoxia, rales, vomiting, and diarrhea were more
common among SARS-CoV–positive patients than SARS-
CoV–negative controls (Table 3). Case-patients were also
significantly more likely than controls to report fever as an
initial symptom (8/8 vs. 29/65; p < 0.01) and to have an
abnormal chest radiograph at the time of first evaluation
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ed to patients with radiographic evidence of pneumonia,
dyspnea and vomiting remained associated with SARS-
CoV infection. In addition, SARS-CoV–positive cases
were significantly more likely to have bilateral multifocal
infiltrates (7/8 cases versus 4/14 controls; p = 0.02) and
radiographic progression of pulmonary infiltrates into
week 2 of illness (6/8 cases versus 0/14 controls; p < 0.01).
Conclusions
We compared the 8 U.S. patients with laboratory-con-
firmed SARS to SARS-CoV–negative controls who met
the clinical and epidemiologic criteria for suspected or
probable SARS. Our findings indicate that SARS-CoV
infection is associated with significant lower respiratory
tract disease. Patients with laboratory-confirmed SARS
were more likely than controls to have dyspnea, hypoxia,
and rales. Patients were also more likely than controls to
have an abnormal chest radiograph at the time of first eval-
uation. These clinical findings are similar to those report-
ed in case series from Asia and Canada, and contrast the
clinical manifestations of SARS-CoV with most viral res-
piratory pathogens including other human coronaviruses
(1–5,10). When compared to controls with radiographic
evidence of pneumonia, patients with SARS were more
likely to manifest dyspnea and progressive bilateral pul-
monary infiltrates. This radiographic progression to multi-
focal infiltrates has been a prominent finding in several
previous studies and may prove to be a hallmark feature of
the later stages of this disease (1–3,6,11). Among U.S.
case-patients, diarrhea and vomiting were also significant-
ly associated with SARS-CoV infection. While gastroin-
testinal symptoms were a relatively uncommon feature in
some previous reports (1,3), diarrhea was frequently
reported in other case series, including a major communi-
ty outbreak at a Hong Kong apartment block (2,4,5,12).
Although previous studies have described the clinical
features of patients with laboratory-confirmed SARS, none
compared the characteristics of these patients with SARS-
CoV–negative controls. Our findings suggest that the com-
bination of gastrointestinal symptoms, dyspnea, and bilat-
eral pulmonary infiltrates may warrant a higher level of
suspicion for SARS-CoV infection. By contrast, patients
with findings of only upper respiratory tract infection may
be unlikely to have SARS. Although moderate lymphope-
nia was prominent among U.S. case-patients, it was also a
fairly common finding among controls who likely had
other viral sources of infection. The small number of per-
sons with laboratory-confirmed SARS in the United States
limited our power to identify independent clinical predic-
tors of SARS-CoV infection. Further data are needed to
describe the full clinical spectrum of SARS-CoV infection
and to clarify when specific clinical findings are most like-
ly to occur during the course of illness (13,14). 
Early recognition of possible SARS-CoV infection and
rapid initiation of infection control precautions are current-
ly the most important strategies for controlling SARS (15).
Identifying persons who warrant further investigation for
SARS-CoV infection may be difficult on the basis of clin-
ical symptoms alone, especially early in the course of ill-
ness. Appropriate preparedness for SARS will thus require
vigilant clinicians and public health officials to integrate
timely epidemiologic information, astute clinical evalua-
tion, and improved laboratory diagnostic tools. 
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